ClinicalTrials.gg
Status unknownNCT05660720Updated Dec 21, 2022

Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects

A Phase 1 interventional study of Orelabrutinib and placebo (orelabrutinib tablet simulator) and Orelabrutinib in Healthy Subject, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-21.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2022), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is A Randomized, Blinded, Placebo- and Positive-Controlled, Four-Period, Crossover-Design Thorough QT/QTc (TQT) Study to Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects

Read the detailed description

This is a randomized, blinded, placebo- and positive-controlled, four-period, crossover clinical study. A double-blind design is used for administration of orelabrutinib tablet and placebo, and an open-label design is used for moxifloxacin hydrochloride tablet.Subjects who meet all inclusion criteria and do not meet any of the exclusion criteria are randomly assigned to one of 12 treatment sequences, and each treatment sequence includes 4 periods, with a 5-day washout period between treatment periods. The subject will complete all the visit examinations on Day 17 after the first dose, then will be discharged from the study site, and will receive telephone follow-up on Day 8 ± 2 after the last dose date. If a subject has clinically significant abnormal examination results when discharging from the study site after the last dose, on-site follow-up is essential to track the abnormal examination results, or otherwise, only telephone follow-up is required.

02

Conditions studied

  • Healthy Subject
03

In context

Lead sponsor

Beijing InnoCare Pharma Tech Co., Ltd. is the lead sponsor of 61 studies on the registry; 37 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. After being informed and understanding of the trial process and possible adverse reactions of the drug, the subjects voluntarily signed an form (ICF) and confirmed their participation in all study procedures;
  2. Healthy subjects aged 18-45 years (inclusive) at the time of signing the informed consent;
  3. Weight of subjects ≥50.0 kg and ≤100.0 kg; (BMI) ≥19.0 kg/m2 and ≤ 30.0 kg/m2, BMI= weight (kg)/height 2 (m2);
  4. Subjects do not have medical history and various examinations including physical examination, vital signs, laboratory tests or , and the results are normal or abnormal without clinical significance judged by investigators.
  5. Eligible fertile subjects (male and female) must agree to abstain from sex (avoid heterosexual sex) or use effective with an annual contraceptive failure rate of less than 1% during the trial period until 3 months after the end of the trial.

Exclusion criteria

Exclusion Criteria

  1. History of any clinically serious disease like heart, liver, kidney, gastrointestinal tract, blood and respiratory system, immune system etc, with a history of fainting during acupuncture or injection or when seeing blood, or cannot tolerate venipuncture;
  2. Abnormal renal ,liver and pancreas function;
  3. Low blood pressure (systolic blood pressure\<90 mmHg; diastolic blood pressure\<60 mmHg) or hypertension (systolic blood pressure ≥ 140 mmHg; diastolic blood pressure ≥ 90 mmHg);
  4. Prolonged that is at risk of causing torsade de pointes (TdP) requires drug treatment or other heart related abnormalities require drug treatment;
  5. The average value of three repetitions of 12 lead at screening and before the first administration exceeded the standard: PR>220 ms, QRS>120 ms, HR\<50 bpm, QTcF>450 ms (male and female), and any ECG abnormality with clinical significance determined by the investigator at screening;
  6. With a history of dysphagia or any gastrointestinal disease that affects drug absorption;
  7. With a history of drug or food allergy, or a history of specific allergies (asthma, urticaria, eczema, etc.); or allergic to moxifloxacin or other fluoroquinolones;
  8. Within 3 months before screening, those who have undergone surgery, have smoked more than 5 cigarettes or e-cigarettes daily, with a history of drug abuse or illicit drug use, or plan to undergo surgery during the study period, or with positive results of urine drug test at screening;
  9. Those who have used any prescription drugs, over-the-counter drugs, Chinese herbal medicines, or health products within 14 days before the first dose;
  10. People with positive results of one or more of the following tests: surface antigen (HBsAg), antibody (HCVAb), antigen/antibody joint test (HIV Ab), Treponema pallidum antibody (TP Ab) and COVID-19 at screening;
  11. Within 1 month before screening, those who have received anticoagulant therapy or thrombin inhibitor and/or antiplatelet therapy, any drug that inhibits or induces the metabolism of a drug by the liver;
  12. Those who have frequently used alcohol within 6 months before screening, or those who are unable to abstain from alcohol during the study period, or those who have positive results of breath alcohol test at the time of screening;
  13. Within 7 days before screening those who have drunk excessive tea, coffee or caffeinated beverages, or who have eaten fruits or food that affect metabolic enzymes, within 1 months before screening who are used to beverages or food rich in xanthine ingredients, and those who are unable to abstain from such beverages, fruits or food mentioned above during the whole study period;
  14. Those who have participated in 4 or more clinical trials during the past one year; who have taken other study drugs or participated in other drug clinical trials within 3 months before screening;
  15. Those who have donated blood or plan to donate blood within 3 months before screening, or have received blood transfusion within 4 weeks before screening;
  16. Those who have been vaccinated within 4 weeks before screening, or plan to get vaccinated during the study period;
  17. Women who are pregnant or breastfeeding, or have positive results of serum human chorionic gonadotropin (HCG) test before the first dose;
  18. Those who disagree to discontinue strenuous exercises from the date of signing the ICF to the end of the trial (including non-hospitalization period);
  19. Those who cannot complete this study due to other reasons or who have lab abnormalities as determined by the investigator, or who are not suitable for this study as assessed by the investigators.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Orelabrutinib tablet 150 mg (study drug) and placebo 250 mg (orelabrutinib tablet simulator)

    The subjects will be dosed once on Day1 or Day6 or Day11 or Day16 according to randomization.

    Drug: Orelabrutinib and placebo (orelabrutinib tablet simulator)

  • Experimental
    Orelabrutinib 400 mg (study drug)

    The subjects will be dosed once on Day1 or Day6 or Day11 or Day16 according to randomization.

    Drug: Orelabrutinib

  • Placebo comparator
    Placebo 400mg (orelabrutinib tablet simulator)

    The subjects will be dosed once on Day1 or Day6 or Day11 or Day16according to randomization.

    Drug: Placebo (orelabrutinib tablet simulator)

  • Active comparator
    Moxifloxacin hydrochloride 400 mg

    he subjects will be dosed once on Day1 or Day6 or Day11 or Day16 according to randomization.

    Drug: Moxifloxacin hydrochloride

Interventions

  • DrugOrelabrutinib and placebo (orelabrutinib tablet simulator)

    Orelabrutinib will be administered as 3 tablets (150mg) and placebo as 5 tablets (250mg)

  • Orelabrutinib will be administered as 8 tablets (400mg)

  • DrugPlacebo (orelabrutinib tablet simulator)

    Placebo will be administered as 8 tablets (400mg).

  • Moxifloxacin hydrochloride will be administered as 1 tablet (400mg)

06

What researchers measure

Primary outcomes

  1. Placebo-corrected change-from-baseline QTcF interval

    Extraction of Holter ECGs from 1 h pre-dose to 24 h post-dose in each period.

    Time frame: Day1, Day2, Day6, Day7, Day11, Day12, Day16 and Day17

Secondary outcomes

  1. Change-from-baseline QTcF, PR, and QRS intervals

    Extraction of Holter ECGs from 1 h pre-dose to 24 h post-dose in each period.

    Time frame: Day1, Day2, Day6, Day7, Day11, Day12, Day16 and Day17

  2. Change-from-baseline HR

    Extraction of Holter ECGs from 1 h pre-dose to 24 h post-dose in each period.

    Time frame: Day1, Day2, Day6, Day7, Day11, Day12, Day16 and Day17

  3. Placebo-corrected change-from-baseline PR, and QRS intervals

    Extraction of Holter ECGs from 1 h pre-dose to 24 h post-dose in each period.

    Time frame: Day1, Day2, Day6, Day7, Day11, Day12, Day16 and Day17

  4. Placebo-corrected change-from-baseline HR

    Extraction of Holter ECGs from 1 h pre-dose to 24 h post-dose in each period.

    Time frame: Day1, Day2, Day6, Day7, Day11, Day12, Day16 and Day17

  5. Categorical outliers for QTcF, PR, and QRS

    Extraction of Holter ECGs from 1 h pre-dose to 24 h post-dose in each period.

    Time frame: Day1, Day2, Day6, Day7, Day11, Day12, Day16 and Day17

  6. Categorical outliers for HR

    Extraction of Holter ECGs from 1 h pre-dose to 24 h post-dose in each period.

    Time frame: Day1, Day2, Day6, Day7, Day11, Day12, Day16 and Day17

  7. Frequency of treatment-emergent changes of T-wave morphology and U-waves presence

    Extraction of Holter ECGs from 1 h pre-dose to 24 h post-dose in each period.

    Time frame: Day1, Day2, Day6, Day7, Day11, Day12, Day16 and Day17

  8. Tmax of Orelabrutinib after single dose

    Plasma samples will be collected from all the subjects for PK analysis. For each period, venous blood will be collected within 30 min pre-dose, and 0.5 h, 1.0 h, 2.0 h, 3.0 h, 4.0 h, 6.0 h, 8.0 h, 12.0 h, and 24.0 h post-dose.

    Time frame: Day1, Day2, Day6, Day7, Day11, Day12, Day16 and Day17

  9. Cmax of Orelabrutinib after single dose

    Plasma samples will be collected from all the subjects for PK analysis. For each period, venous blood will be collected within 30 min pre-dose, and 0.5 h, 1.0 h, 2.0 h, 3.0 h, 4.0 h, 6.0 h, 8.0 h, 12.0 h, and 24.0 h post-dose.

    Time frame: Day1, Day2, Day6, Day7, Day11, Day12, Day16 and Day17

  10. AUC of Orelabrutinib after single dose

    Plasma samples will be collected from all the subjects for PK analysis. For each period, venous blood will be collected within 30 min pre-dose, and 0.5 h, 1.0 h, 2.0 h, 3.0 h, 4.0 h, 6.0 h, 8.0 h, 12.0 h, and 24.0 h post-dose.

    Time frame: Day1, Day2, Day6, Day7, Day11, Day12, Day16 and Day17

  11. T1/2 of Orelabrutinib after single dose

    Plasma samples will be collected from all the subjects for PK analysis. For each period, venous blood will be collected within 30 min pre-dose, and 0.5 h, 1.0 h, 2.0 h, 3.0 h, 4.0 h, 6.0 h, 8.0 h, 12.0 h, and 24.0 h post-dose.

    Time frame: Day1, Day2, Day6, Day7, Day11, Day12, Day16 and Day17

  12. CL/F of Orelabrutinib after single dose

    Plasma samples will be collected from all the subjects for PK analysis. For each period, venous blood will be collected within 30 min pre-dose, and 0.5 h, 1.0 h, 2.0 h, 3.0 h, 4.0 h, 6.0 h, 8.0 h, 12.0 h, and 24.0 h post-dose.

    Time frame: Day1, Day2, Day6, Day7, Day11, Day12, Day16 and Day17

  13. Vz/F of Orelabrutinib after single dose

    Plasma samples will be collected from all the subjects for PK analysis. For each period, venous blood will be collected within 30 min pre-dose, and 0.5 h, 1.0 h, 2.0 h, 3.0 h, 4.0 h, 6.0 h, 8.0 h, 12.0 h, and 24.0 h post-dose.

    Time frame: Day1, Day2, Day6, Day7, Day11, Day12, Day16 and Day17

  14. Tmax of moxifloxacin after single dose

    Plasma samples will be collected from all the subjects for PK analysis. For each period, venous blood will be collected within 30 min pre-dose, and 0.5 h, 1.0 h, 2.0 h, 3.0 h, 4.0 h, 6.0 h, 8.0 h, 12.0 h, and 24.0 h post-dose.

    Time frame: Day1, Day2, Day6, Day7, Day11, Day12, Day16 and Day17

  15. Cmax of moxifloxacin after single dose

    Plasma samples will be collected from all the subjects for PK analysis. For each period, venous blood will be collected within 30 min pre-dose, and 0.5 h, 1.0 h, 2.0 h, 3.0 h, 4.0 h, 6.0 h, 8.0 h, 12.0 h, and 24.0 h post-dose.

    Time frame: Day1, Day2, Day6, Day7, Day11, Day12, Day16 and Day17

  16. AUC of moxifloxacin after single dose

    Plasma samples will be collected from all the subjects for PK analysis. For each period, venous blood will be collected within 30 min pre-dose, and 0.5 h, 1.0 h, 2.0 h, 3.0 h, 4.0 h, 6.0 h, 8.0 h, 12.0 h, and 24.0 h post-dose.

    Time frame: Day1, Day2, Day6, Day7, Day11, Day12, Day16 and Day17

  17. T1/2 of moxifloxacin after single dose

    Plasma samples will be collected from all the subjects for PK analysis. For each period, venous blood will be collected within 30 min pre-dose, and 0.5 h, 1.0 h, 2.0 h, 3.0 h, 4.0 h, 6.0 h, 8.0 h, 12.0 h, and 24.0 h post-dose.

    Time frame: Day1, Day2, Day6, Day7, Day11, Day12, Day16 and Day17

  18. CL/F of moxifloxacin after single dose

    Plasma samples will be collected from all the subjects for PK analysis. For each period, venous blood will be collected within 30 min pre-dose, and 0.5 h, 1.0 h, 2.0 h, 3.0 h, 4.0 h, 6.0 h, 8.0 h, 12.0 h, and 24.0 h post-dose.

    Time frame: Day1, Day2, Day6, Day7, Day11, Day12, Day16 and Day17

  19. Vz/F of moxifloxacin after single dose

    Plasma samples will be collected from all the subjects for PK analysis. For each period, venous blood will be collected within 30 min pre-dose, and 0.5 h, 1.0 h, 2.0 h, 3.0 h, 4.0 h, 6.0 h, 8.0 h, 12.0 h, and 24.0 h post-dose.

    Time frame: Day1, Day2, Day6, Day7, Day11, Day12, Day16 and Day17

  20. Serious adverse events (SAEs) occurring from administration of drugst to follow-up period or early withdrawal, incidence of treatment-emergent adverse events

    SAE and TEAE

    Time frame: Through study completion, an average of 1 year

07

Study locations

1 site
  • Beijing GoBroad Boren Hospital
    Beijing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2022 (actual). Primary completion is estimated for Jun 2023, 7 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2022
First posted
Dec 21, 2022
StartActual
Nov 19, 2022
Primary completionEst.
Jun 30, 2023
CompletionEst.
Aug 31, 2023
Last update
Dec 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05660720
Responsible party
Sponsor
First posted
Dec 21, 2022
Start date
Nov 19, 2022
Primary completion
Jun 30, 2023 (estimated)
Completion
Aug 31, 2023 (estimated)
Last update
Dec 21, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orelabrutinib

Start the discussion